Stevanato Group S.p.A. (STVN) is a Medical/Dental Instruments company listed on NYSE. In the last 30 days Quantisnow tracked 8 wire items for STVN, including 3 SEC filings, 2 earnings updates and 1 press release or news item. The most recent was published Nov 10, 2026.
STVN rankings
Financial highlights
Full financials- Revenue, FY2025
- €1.19B
- Revenue growth
- +7.4%
- Net income, FY2025
- €139.84M
- Net margin
- 11.8%
- Free cash flow, FY2025
- €22.32M
- Cash
- €130.60M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks39+300%
2026-05-172026-11-08
Mix1390d
- Other3(23%)
- Analyst3(23%)
- SEC Filings3(23%)
- Insider2(15%)
- Earnings2(15%)
Activity · 52 weeks7438 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERDirector Morel Donald E Jr bought $326,750 worth of Ordinary Shares (25,000 units at $13.07), increasing direct ownership by 67% to 62,424 units (SEC Form 4)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- ANALYSTStevanato Group S.p.A. downgraded by William BlairWilliam Blair downgraded Stevanato Group S.p.A. from Outperform to Mkt Perform
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- PRStevanato Group Delivers 8% Revenue Growth for the Third Quarter of Fiscal 2026The Company Maintains Fiscal Year 2026 Guidance Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the third quarter of 2026. Third Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €326.1 million, and on an organic basis* revenue increased 8%. Revenue from high-value solutions represented 46% of total revenue. Gross profit was €95.0 million and gross profit margin was 29.1%. Adjusted EBITDA margin increased 150 basis points to 27.2%. Diluted earnings per sh
- PRStevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System SelectionJoint system-level testing combines Stevanato Group’s glass syringes with Aptar Pharma’s elastomer components to provide key data earlier in development and help inform packaging decisions for sensitive biologics and other injectable therapiesStevanato Group S.p.A. (NYSE:STVN) (the "Company"), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced a collaboration with Aptar Pharma to provide system-level data supporting earlier evaluation of pre-filled syringe configurations for biotech and pharmaceutical companies, with a focus on sensitive biologics and other injectable thera
- PRStevanato Group to Report Third Quarter 2026 Financial Results on November 3, 2026Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the third quarter of 2026 on Tuesday, November 3, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, November 3, 2026, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pr
- ANALYSTDeutsche Bank initiated coverage on Stevanato Group S.p.A.Deutsche Bank initiated coverage of Stevanato Group S.p.A. with a rating of Hold
- INSIDEROfficer Stocchi Mauro sold $293,454 worth of Ordinary Shares (13,649 units at $21.50), decreasing direct ownership by 3% to 400,000 units (SEC Form 4)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- ANALYSTUBS initiated coverage on Stevanato Group S.p.A.UBS initiated coverage of Stevanato Group S.p.A. with a rating of Neutral
- PRStevanato Group to Participate in Two Upcoming Investor ConferencesStevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in two upcoming investor conferences: Tuesday, September 15, at 1:50 p.m. (ET) – Morgan Stanley Annual Global Healthcare Conference, New York, NY Tuesday, September 22, at 8:25 – 9:05 a.m. (GMT) – BofA Global Healthcare Conference, London, UK A live webcast for each event will be available on the Company’s website at www.stevanatogroup.com under the "Investors" section. A replay of the webcast will be available for approximately 90 days after the event.
- SECSEC Form SCHEDULE 13G filed by Stevanato Group S.p.A.SCHEDULE 13G - Stevanato Group S.p.A. (0001849853) (Subject)
- INSIDERDirector Magistretti Elisabetta sold $41,084 worth of Ordinary Shares (2,045 units at $20.09), decreasing direct ownership by 41% to 2,930 units (SEC Form 4) to cover taxes4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERChief Financial Officer Dal Lago Marco sold $84,559 worth of Ordinary Shares (4,209 units at $20.09), decreasing direct ownership by 5% to 81,144 units (SEC Form 4) to cover withholding tax4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- INSIDERDirector Santel Luciano sold $40,642 worth of Ordinary Shares (2,023 units at $20.09), decreasing direct ownership by 30% to 4,739 units (SEC Form 4) (withholding tax)4 - Stevanato Group S.p.A. (0001849853) (Issuer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form 6-K filed by Stevanato Group S.p.A.6-K - Stevanato Group S.p.A. (0001849853) (Filer)
- SECSEC Form SCHEDULE 13G filed by Stevanato Group S.p.A.SCHEDULE 13G - Stevanato Group S.p.A. (0001849853) (Subject)
- PRStevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026- The Company Divests its California-Based Subsidiary, Balda C. Brewer, Inc - Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the second quarter of 2026. Second Quarter of 2026 Highlights (comparisons to prior-year period) Revenue increased 8% to €302.0 million, with high-value solutions representing 45% of total revenue. Gross profit margin increased 60 basis points to 28.7%. Adjusted EBITDA margin increased 280 basis points to 26.0%. The Company completed the divestiture of its California-ba
- PRLiraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Received Marketing Authorizations in Multiple European CountriesThe regulatory approvals cover therapies for diabetes and weight management, further expanding the commercial adoption of Stevanato Group's proprietary Alina® pen injector platform across Europe. Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life sciences industries, today announced that liraglutide-based combination products incorporating Stevanato Group’s proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations relate to finished combination products held by the respective Marketing Authorization Holders. This press r
- PRStevanato Group to Report Second Quarter 2026 Financial Results on August 4, 2026Stevanato Group S.p.A. (NYSE:STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the second quarter of 2026 on Tuesday, August 4, 2026, at 6:30 a.m. (EDT). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (EDT) on Tuesday, August 4, 2026, to discuss financial results. During the call, management will refer to a slide presentation which will be available on the morning of the call on the "Financial Results" page under the Company's Investor Relations section of its website. Pre-r
- INSIDERDirector Balachandran Madhavan was granted 4,975 units of Ordinary Shares and sold $25,515 worth of Ordinary Shares (1,493 units at $17.09), increasing direct ownership by 5% to 69,458 units (SEC Form 4) to satisfy withholding obligation4 - Stevanato Group S.p.A. (0001849853) (Issuer)
STVN FAQ
11 questionsWhat does Stevanato Group S.p.A. do?
Stevanato Group S.p.A. engages in the design, production, and distribution of products and systems to provide integrated solutions for pharma and healthcare. Its principal products are linked to containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machine. Stevanato Group S.p.A. was founded in 1949 and is based in Piombino Dese, Italy.What is the latest news on STVN?
In the last 30 days Quantisnow tracked 8 wire items for STVN: 3 SEC filings, 2 earnings updates, 1 press release or news item and 1 analyst rating. The most recent was published on November 10, 2026.What is STVN revenue?
Stevanato Group S.p.A. (STVN) reported €1.19B of revenue for fiscal 2025 (ended Dec 31, 2025). That is up 7.4% from the year before.Is STVN profitable?
Yes. Stevanato Group S.p.A. earned €139.84M in net income for fiscal 2025 (ended Dec 31, 2025), a net margin of 11.8%.How much cash and debt does STVN have?
Stevanato Group S.p.A. reported €130.60M in cash and cash equivalents and €455.15M of debt on its most recent balance sheet in SEC filings.Where does STVN stock trade?
Stevanato Group S.p.A. (STVN) is listed on NYSE.What sector and industry is STVN in?
Stevanato Group S.p.A. operates in the Health Care sector, Medical/Dental Instruments industry.When did Stevanato Group S.p.A. go public?
Stevanato Group S.p.A. (STVN) completed its IPO in 2021.What are analysts saying about STVN?
Across the last 8 analyst actions on Stevanato Group S.p.A., there were 0 upgrades and 1 downgrade. The most recent action was from William Blair: Mkt Perform on 2026-11-04. Recent price targets range from $21.00 to $28.00.What companies are similar to STVN?
Notable peers in the same industry include DXCM (DexCom Inc.), SYK (Stryker Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.), MMM (3M Company). Compare STVN side-by-side with any of them on Quantisnow.How can I track STVN on Quantisnow?
Quantisnow aggregates Stevanato Group S.p.A.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow STVN to receive live email and push alerts on every new disclosure.